Ikonisys becomes distributor of oncoFISH cancer test
This article was originally published in Clinica
Executive Summary
Ikonisys has become the distributor of Clinical Laboratory Partners’ oncoFISH cervical cancer test as part of an exclusive licensing deal. The assay is a companion test designed to work alongside existing cervical cancer screening tests like Pap smear and HPV tests prior to colposcopy. Under the terms of the partnership, Newington, Connecticut-based Clinical Laboratory Partners will market the assay to physicians for the analysis of specimens from liquid-based Pap tests classified as low-grade squamous intraepithelial lesion (LSIL). Ikonisys (New Haven, Connecticut) will conduct the evaluation of the specimen using its Ikoniscope digital microscopy system. The oncoFISH test will assist in determining if there is a risk of progression to cervical cancer or if the lesion will naturally regress, by identifying a genetic marker linked to increased likelihood of cervical cancer.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals